3-Bromo-5-aminobenzotrifluoride CAS 54962-75-3

Product Description:

Product Name: 3-Bromo-5-aminobenzotrifluoride CAS NO: 54962-75-3

Synonyms:

BenzenaMine,3-broMo-5-(trifluoroMethyl)-;

3-Bromo-5-(trifluoromethyl)aniline, 5-Bromo-alpha,alpha,alpha-trifluoro-m-toluidine;

3-AMino-5-broMobenzotrifluoride[3-BroMo-5-(trifluoroMethyl)aniline];

Chemical & Physical Properties:

Appearance: Colorless clear liquid

Assay :≥98.0%

Density: 1.697

Boiling Point: 220-223℃

Flash Point: >110℃

Refractive Index: 1.528

Safety Information:

WGK Germany: 3

Signal Word: Warning

Safety Statements: S26-S36

Risk Statements: R36/37/38

HS Code: 2921420090

Hazard Codes: Xi

Hazard Statements: H315-H319-H335

Precautionary Statements: P261-P305 + P351 + P338

3-amino-5-bromotrifluorotoluene is an intermediate for nilotinib, a selective tyrosine kinase inhibitor that targets BCR-ABL kinase, C-KIT, and platelet-derived growth factor receptor (PDGFR); It has no campaign against the SRC family. Nillotinib inhibits the proliferation of leukemia cell lines mediated by BCR-ABL by binding to the ATP-binding site of BCR-ABL and inhibiting tyrosine kinase activity, showing the activity of anti-imatinib-resistant BCR-ABL kinase mutation. Nillotinib is used for the treatment of newly diagnosed Philadelphia chromosomal positive (PH +) chronic myelogenous leukemia (CML) in children and adults aged 1 years or older. Treatment Chronic and accelerated Philadelphia adults with chromosomal positive CML who were resistant or intolerant to prior therapy, including imatinib. Children with chronic Philadelphia-positive CML for ≥1 year were resistant or intolerant to previous tyrosine kinase inhibitor therapy. Philadelphia is chromosomal positive (pH +) acute lymphoblastic leukemia (ALL). Gastrointestinal stromal tumor (GIST) (refractory).

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.